NASDAQ: KPRXKiora Pharmaceuticals Inc Stock
$3.02-0.06 (-1.95%)
Updated Jun 13, 2025
KPRX Price
$3.02
Fair Value Price
N/A
Market Cap
$9.19M
52 Week Low
$2.51
52 Week High
$5.45
P/E
-1x
P/B
0.39x
P/S
634.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.00k
Earnings
-$12.05M
Gross Margin
100%
Operating Margin
-49,209.99%
Profit Margin
-60,257.3%
Debt to Equity
0.44
Operating Cash Flow
-$8M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KPRX Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KPRX's potential to beat the market
- KPRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KPRX
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important KPRX news, forecast changes, insider trades & much more!
KPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KPRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KPRX is good value based on its book value relative to its share price (0.39x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KPRX due diligence checks available for Premium users.
Valuation
KPRX fair value
Fair Value of KPRX stock based on Discounted Cash Flow (DCF)
Price
$3.02
Fair Value
$10.68
Undervalued by
71.71%
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1x
Industry
-108.97x
Market
31.36x
KPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
4.66x
KPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.2M
Profit Margin
0%
KPRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KPRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$34.0M
Liabilities
$10.3M
Debt to equity
0.44
KPRX's short-term assets ($27.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPRX's short-term assets ($27.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$2.7M
Financing
$0.0
KPRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KPRX vs Biotech Stocks
Kiora Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.